Literature DB >> 30901007

Folate-targeted pH-sensitive bortezomib conjugates for cancer treatment.

Yin Liu1, Zhi Dai, Jiao Wang, Ying Tu, Lin Zhu.   

Abstract

In this study, a folate-targeted pH-sensitive bortezomib conjugate was developed for cancer-specific drug delivery and therapy. The conjugate showed improved cellular uptake, penetration, and anticancer activity compared to free bortezomib, a bortezomib-mannitol derivative, and a PEGylated bortezomib conjugate in folate receptor overexpressing cancer cells and their 3D spheroids.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30901007      PMCID： PMC6543544          DOI： 10.1039/c9cc01344j

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN： 1359-7345            Impact factor:   6.222


  24 in total

Review 1.  The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction.

Authors:  Michael H Glickman; Aaron Ciechanover
Journal:  Physiol Rev       Date:  2002-04       Impact factor: 37.312

Review 2.  The development of proteasome inhibitors as anticancer drugs.

Authors:  Julian Adams
Journal:  Cancer Cell       Date:  2004-05       Impact factor: 31.743

3.  Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.

Authors:  J C Cusack; R Liu; M Houston; K Abendroth; P J Elliott; J Adams; A S Baldwin
Journal:  Cancer Res       Date:  2001-05-01       Impact factor: 12.701

4.  Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors.

Authors:  Holger Rumpold; Christina Salvador; Anna Maria Wolf; Herbert Tilg; Guenther Gastl; Dominik Wolf
Journal:  Biochem Biophys Res Commun       Date:  2007-07-23       Impact factor: 3.575

5.  Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer.

Authors:  C Aghajanian; D S Dizon; P Sabbatini; J J Raizer; J Dupont; D R Spriggs
Journal:  J Clin Oncol       Date:  2005-09-01       Impact factor: 44.544

6.  The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status.

Authors:  Patricia Pérez-Galán; Gaël Roué; Neus Villamor; Emili Montserrat; Elias Campo; Dolors Colomer
Journal:  Blood       Date:  2005-09-15       Impact factor: 22.113

Review 7.  Drug penetration in solid tumours.

Authors:  Andrew I Minchinton; Ian F Tannock
Journal:  Nat Rev Cancer       Date:  2006-08       Impact factor: 60.716

Review 8.  Drug resistance and the solid tumor microenvironment.

Authors:  Olivier Trédan; Carlos M Galmarini; Krupa Patel; Ian F Tannock
Journal:  J Natl Cancer Inst       Date:  2007-09-25       Impact factor: 13.506

Review 9.  A review of folate receptor alpha cycling and 5-methyltetrahydrofolate accumulation with an emphasis on cell models in vitro.

Authors:  Barton A Kamen; Angel K Smith
Journal:  Adv Drug Deliv Rev       Date:  2004-04-29       Impact factor: 15.470

Review 10.  Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases.

Authors:  Philip S Low; Walter A Henne; Derek D Doorneweerd
Journal:  Acc Chem Res       Date:  2007-07-27       Impact factor: 22.384
View more
  2 in total

Review 1.  Targeted Delivery Methods for Anticancer Drugs.

Authors:  Valery V Veselov; Alexander E Nosyrev; László Jicsinszky; Renad N Alyautdin; Giancarlo Cravotto
Journal:  Cancers (Basel)       Date:  2022-01-26       Impact factor: 6.639

Review 2.  Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations.

Authors:  Jianhao Liu; Ruogang Zhao; Xiaowen Jiang; Zhaohuan Li; Bo Zhang
Journal:  Biomolecules       Date:  2021-12-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.